Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argenica Therapeutics Ltd ( (AU:AGN) ) has provided an update.
Argenica Therapeutics has reached a significant milestone in its Phase 2 clinical trial of ARG-007 for acute ischaemic stroke, with the final patient dosed and results expected in Q3 2025. The company also reported positive preclinical results for ARG-007 in treating moderate traumatic brain injury and received $1.5 million in funding from the Australian Government. Despite a clinical hold on its IND application by the FDA, the current trial in Australia remains unaffected. With $10.5 million in cash reserves, Argenica is well-positioned to complete its ongoing trials and continue its research into neurological therapies.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a biotechnology company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other brain injuries. The company is actively engaged in clinical trials and research projects, with a primary market focus on acute ischaemic stroke (AIS) and other neurological conditions. Argenica has secured significant non-dilutive funding from government and philanthropic sources to support its research endeavors.
Average Trading Volume: 94,901
Technical Sentiment Signal: Sell
Find detailed analytics on AGN stock on TipRanks’ Stock Analysis page.